Related Experiment Video
Updated: May 19, 2026
Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Published on: June 5, 2012
Pseudomonas aeruginosa serology and risk for re-isolation in the EPIC trial
Michael Anstead1, Sonya L Heltshe2, Umer Khan3
1Department of Pediatrics, University of Kentucky, Lexington KY 40563-0284, USA.
Insights
Pseudomonas aeruginosa serology may help monitor recurrence in cystic fibrosis (CF) patients. Positive serology for specific antigens, like alkaline protease and exotoxin A, indicates a higher risk of P. aeruginosa returning after treatment.
Area of Science:
- Clinical Microbiology
- Infectious Diseases
- Cystic Fibrosis Research
Background:
- The prognostic significance of Pseudomonas aeruginosa serology in cystic fibrosis (CF) patients undergoing antibiotic therapy remains unclear.
- Early detection and management of P. aeruginosa are crucial in CF patient care.
Purpose of the Study:
- To evaluate the predictive value of P. aeruginosa serology for antibiotic therapy outcomes in CF patients.
- To determine if serology can predict treatment failure, time to pulmonary exacerbation, or risk of recurrent P. aeruginosa isolation.
Main Methods:
- Utilized five antigens across two ELISAs to assess P. aeruginosa serology in CF patients from the EPIC trial.
- Correlated baseline seropositivity with initial eradication failure, time to pulmonary exacerbation, and recurrent P. aeruginosa isolation post-eradication.
Main Results:
- Baseline P. aeruginosa serology did not significantly predict initial eradication failure.
- Seropositivity to alkaline protease and exotoxin A antigens was significantly linked to an increased risk of recurrent P. aeruginosa isolation (p=0.003 and p=0.001).
- No association was found between baseline seropositivity and the time to pulmonary exacerbation.
Conclusions:
- P. aeruginosa serology, particularly for specific antigens, shows potential as a complementary tool for monitoring P. aeruginosa recurrence in CF patients.
- Serology may aid clinicians in managing early P. aeruginosa infections and preventing relapse.
Background:
The prognostic value of Pseudomonas aeruginosa serology for antibiotic therapy in cystic fibrosis patients is not well understood.
Methods:
Using five antigens from two ELISAs, we assessed whether positive serology in CF patients participating in the multi-center Early Pseudomonas Infection in Children (EPIC) trial would predict treatment failure, time to pulmonary exacerbation and risk for recurrent P. aeruginosa isolation post eradication.
Results:
Baseline positive P. aeruginosa serology was not significantly associated with failure of initial P. aeruginosa eradication measured at week 10 (adjusted for baseline culture) but seropositivity to the antigens alkaline protease and exotoxin A was significantly associated with increased risk for recurrent P. aeruginosa isolation during the 60 week post eradication follow-up period (p=0.003 and p=0.001 respectively). There was no association between baseline seropositivity and time to pulmonary exacerbation.
Conclusion:
P. aeruginosa serology may complement culture results in clinicians' efforts to successfully monitor recurrence of early P. aeruginosa in CF patients.
Related Concept Videos
01:14Atypical Pneumonia
01:25Clinical Significance of Antibiotic Resistance
01:30Pneumonia III: Complications and Assessment